Arylsulfonylamino hydroxamic acid derivatives

A method of treating cancer, in a mammal, comprising administering to said mammal an amount of a compound of the formula ##STR9## wherein n is 1 to 6;

• X is hydroxy, (C.sub.1 -C.sub.6)alkoxy or NR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)aryl(C.sub.6 -C.sub.10)aryl, (C.sub.6 -C.sub.10)aryl(C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.6)cycloalkyl, (C.sub.3 -C.sub.6)cycloalkyl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.5)alkyl(CHR.sup.5)(C.sub.1 C.sub.6)alkyl and CH(R.sup.7)COR.sup.8 ;
• R.sup.1 and R.sup.2 may be taken together to form piperazinyl;
• R.sup.1 and R.sup.2 may be taken together to form an azetidinyl, pyrrokidinyl, morpholinyl, thiomorpholinyl, (C.sub.1 -C.sub.6)alkylpiperazinyl or (C.sub.6 -C.sub.10)arylpiperazinyl;
• R.sup.3 and R.sup.4 are each independently selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl, trifluoromethyl,trifluoromethyl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl(difluoromethylene), (C.sub.1 -C.sub.3 alkyl(difluoromethylene)(C.sub.1 -C.sub.3)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)aryl(C.sub.6 -C.sub.10)aryl, (C.sub.1 -C.sub.6)acyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)acylamino(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkoxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylthio(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arylthio(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylsulfinyl(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arysulfinyl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkysulfonyl(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arysulfonyl(C.sub.1 -C.sub.6)alkyl, amino(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylamino(C.sub.1 -C.sub.6)alkyl, ((C.sub.1 -C.sub.6)alkylamino).sub.2 (C.sub.1 -C.sub.6)alkyl, R.sup.13 CO(C.sub.1 -C.sub.6)alkyl wherein R.sup.13 is R.sup.20 O or R.sup.20 R.sup.21 N wherein R.sup.20 and R.sup.21 are each independently selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl and (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl;
• or R.sup.3 R.sup.4, or R.sup.20 and R.sup.21 may be taken together to form a (C.sub.3 -C.sub.6)cycloalkyl, oxacyclohexyl or thiocyclohexyl;
• wherein R.sup.5 is hydroxy, (C.sub.1 -C.sub.6)acyloxy, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)acylamino, (C.sub.1 -C.sub.6)alkylthio, (C.sub.6 -C.sub.10)arylthio, (C.sub.1 -C.sub.6)alkylsulfinyl, (C.sub.6 -C.sub.10)arylsulfinyl, (C.sub.1 -C.sub.6)alkylsulfoxyl, (C.sub.6 -C.sub.10)arylsulfoxyl, amino, (C.sub.1 -C.sub.6)alkylamino or ((C.sub.1 -C.sub.6)alkyl).sub.2 amino;
• wherein R.sup.7 is hydrogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylthio(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arylthio(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylsulfinyl(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arylsulfinyl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylsulfonyl(C.sub.1 -C.sub.6)alkyl, (C.sub.6 -C.sub.10)arylsulfonyl(C.sub.1 -C.sub.6)alkyl, hydroxy(C.sub.1 -C.sub.6)alkyl, amino(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylamino(C.sub.1 -C.sub.6)alkyl, ((C.sub.1 -C.sub.6)alkyl).sub.2 amino(C.sub.1 -C.sub.6)alkyl, R.sup.9 R.sup.10 NCO(C.sub.1 -C.sub.6)alkyl or R.sup.9 OCO(C.sub.1 -C.sub.6)alkyl;
• R.sup.8 R.sup.11 O or R.sup.11 R.sup.12 N wherein R.sup.11 and R.sup.12 are each independently selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl and (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl;
• R.sup.9 and R.sup.10 are each independently selected from the group consisting of hydrogen, (C.sub.1 -C.sub.6)alkyl and (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl;
• and
• Ar is (C.sub.6 -C.sub.10)aryl, (C.sub.1 -C.sub.6)alkyl(C.sub.6 -C.sub.10)aryl, (C.sub.1 -C.sub.6)alkoxy(C.sub.6 -C.sub.10)aryl, ((C.sub.1 -C.sub.6)alkoxy).sub.2 (C.sub.6 -C.sub.10)aryl or (C.sub.6 -C.sub.10)aryloxy(C.sub.6 -C.sub.10)aryl,
• with the proviso that when either R.sup.1 or R.sup.2 is CH(R.sup.7)COR.sup.8 wherein R.sup.1 and R.sup.5 are as defined above, the other of R.sup.1 or R.sup.2 is hydrogen, (C.sub.1 -C.sub.6)alkyl or benzyl or a pharmaceutically acceptable salt thereof effective in treating such a condition.